{"schema_version":"secwatch.filing_event.v1","accession":"0001711279-26-000044","form_type":"8-K","ticker":"KRYS","cik":"0001711279","company_name":"Krystal Biotech, Inc.","filed_at":"2026-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.788951+00:00","generated_at":"2026-05-14T23:57:00.460210+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Krystal Biotech Q1 2026 revenue $116.4M (+32% YoY); net income $55.9M; pipeline updates","bullets":["VYJUVEK global revenue $116.4M, up 32% YoY from $88.2M; gross margin 95%.","Net income $55.9M ($1.83 diluted EPS) vs $35.7M ($1.20) in Q1 2025; cash $1.0B.","FDA granted platform technology designation for KB407 (CF) and KB111 (HHD) program vectors.","KB803 (DEB corneal abrasions) fully enrolled; top-line data expected 4Q 2026. KB801 (NK) data before year end.","FY 2026 non-GAAP R&D+SG&A guidance $175-195M; KB407 open-label study starting, KB111 HALITE-1 initiating."],"urls":{"canonical":"https://secwatch.observer/filing/0001711279-26-000044","json":"https://secwatch.observer/filing/0001711279-26-000044.json","markdown":"https://secwatch.observer/filing/0001711279-26-000044.md","text":"https://secwatch.observer/filing/0001711279-26-000044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000044/0001711279-26-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000044/krys-20260504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:57:00.460210+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9b7fcf238ec3c422c3b9ad1f1acb2c3a68b8cc9d","claim":"Krystal Biotech, Inc. reported first quarter ending March 31, 2026 results: revenue $116.4 million.","evidence_excerpt":"Krystal Biotech Announces First Quarter 2026 Financial and Operating Results $116.4 million in 1Q VYJUVEK global revenue and $846.7 million since launch","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000044/0001711279-26-000044-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ending March 31, 2026"},{"label":"Revenue","value":"$116.4 million"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}